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Ascitic fluid concentrations of cholesterol, triglycer- 
ides and phospholipids, were compared with ascitic fluid 
total protein in 40 patients with chronic liver disease, 
51 patients with various neoplasms and 1 patient with 
cardiac failure. Seven patients with both chronic liver 
disease and malignancy were considered separately. The 
first 64 patients (23 cirrhotic and 31 with malignancy) 
were u88d to determine median values and ranges and 
to define the most suitable cutoff concentrations be- 
tween both groups. Median values for cholesterol (75 
mg per dl), phospholipids 0.79 mmole per liter), triglyc- 
erides (75 mg per dl) and protein (3.8 gm per dl) were 
higher in malignant ascites compared to ascitic fluid 
concentrations of cholesterol (20 mg per dl), phospholip- 
ids (0.33 mmole per liter), triglycerides (51 mg per dl) 
and protein (1.9 gm per dl) in patients with cirrhosis. 
The best discrimination values were 48 mg per dl for 
cholesterol, 0.6 mmole per liter for phospholipids, 65 
mg per dl for triglycerides and 2.5 gm per dl for protein. 
Application of these cutoff points to 38 subsequent pa- 
tients (17 cirrhotic, l with cardiac failure and 20 with 
malignancy) revealed an efficiency of 86.8% for choles- 
terol, 86.8% for phospholipids, 68.4% for triglycerides 
and 79.0% for protein. From the data of all 92 patients, 
an efficiency of 92.3% for cholesterol, 79.4% for phos- 
pholipids, 72.8% for triglycerides and 79.4% for protein 
was calculated. 
W e  conclude that ascitic fluid cholesterol determi- 
nation offers an excellent, cost-effective discrimina- 
tion of ascites due to cirrhosis vs. ascites caused by 
malignancies. 
Ascites is most often caused by either chronic liver 
disease or malignant neoplasms, and ascitic fluid (AF) 
parameters valuable for the differential diagnosis of these 
have long been sought. Cytological investigation, despite 
its high specificity, has been found unreliable in many 
cases due to the high percentage of false-negative results 
(1). 
AF total protein has been used widely as a laboratory 
test in this differential diagnosis (2, 3). However, high 
protein ascites, although a consistent finding in malig- 
nant AF, has been reported in up to 25% of patients with 
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chronic liver disease (4 ,5) .  Other parameters such as AF 
lactate dehydrogenase, carcinoembryonic antigen or fi- 
brinogen degradation products have been investigated, 
but a complete separation between malignant and cir- 
rhotic ascites has not been achieved (6-10). Lipid anal- 
ysis in AF has been performed only in a few studies 
demonstrating elevated concentrations of total lipids as 
well as cholesterol in ascites of malignant origin com- 
pared to ascites caused by chronic liver disease ( 3 , l l ) .  
Nevertheless, the diagnostic value of lipid determina- 
tion in AF has not been evaluated further. The purpose 
of the present study was to investigate the efficacy of AF 
lipid analysis in discriminating between malignant as- 
cites from ascites caused by cirrhosis. 
MATERIALS AND METHODS 
Patients. Ninety-nine consecutive ascitic patients (51 
with neoplasms metastatic to the peritoneum, 40 with cirrhotic 
ascites and 1 with cardiac failure) were studied prospectively. 
Seven patients with ascites suffered from both: chronic liver 
disease and malignancies. As the cause of ascites could not be 
clearly classified, they were considered separately. The first 54 
patients (23 cirrhotic and 31 with malignancy) were analyzed 
to determine median values and ranges and to define threshold 
concentrations for cholesterol, phospholipids, triglycerides and 
total protein between both groups. The group with chronic liver 
disease consisted of 12 patients with alcoholic and 10 patients 
with posthepatitic cirrhosis and 1 patient with Budd-Chiari 
syndrome. In the 31 patients with malignant ascites, there were 
12 subjects with ovarian carcinoma, 11 with breast cancer and 
8 with carcinoma of the pancreas, gallbladder, esophagus, stom- 
ach or uterus and peritoneal mesothelioma, teratoma and 0s- 
teosarcoma, respectively. 
For further evaluation of the results obtained in the first 54 
patients, an independent group of 38 patients (17 cirrhotic, 1 
cardiac and 20 with maligancy) was studied consecutively. 
Diagnoses in all patients with liver disease were confirmed 
by liver biopsy. Hepatic malignancy was excluded in these 
patients by ultrasound, scintigraphy, or computer tomography 
and, in some, by laparoscopy and autopsy. Patients with ascites 
classified as malignant had a primary or metastatic malignancy 
in the abdomen or pelvis. In some of these patients, the defin- 
itive diagnosis was made at autopsy. 
Cytological examination was performed within 
2 hr of aspiration of AF on Papanicolaou and Giemsa-stained 
smears of the sediment which was obtained by centrifugation 
of 10 to 20 mi samples at 3,000 rpm for 10 min. The supernatant 
was stored at -80°C for further biochemical analysis. 
Total protein was determined by a commercial biuret method 
(Merck, Darmstadt, Federal Republic of Germany). Phospho- 
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lipids were measured after extraction (chloroform-methanol 
3:1, v/v) by phosphorus analysis (12). Triglycerides and choles- 
terol were quantitated enzymatically with commercial test kits 
(Boehringer Mannheim, Federal Republic of Germany) (13, 
14). As there was no random distribution of data, the results 
are given as median and range in addition to mean and standard 
deviation. For further statistical analysis, the Mann-Whitney 
test was used. A p value of <0.05 was considered statistically 
significant. 
The data of the first 54 patients were used to determine the 
most suitable discriminating concentrations for AF lipids and 
protein. Applying these limits to the 38 patients subsequently 
studied and to the total of 92 patients permitted classification 
into four categories: true positive (a); true negative (b); false 
positive (c), and false negative (d). 
Sensitivity was calculated as [a/(a + d)] x 100, specificity as 
[b/(b + c)] x 100 and efficiency as [a + b/(a + b + c + d)] x 
100 (15). 
RESULTS 
Concentrations of the determined parameters in the 
AF of the first 54 patients are illustrated in Figure 1. 
Median values for cholesterol (75 mg per dl), phospholip- 
ids (0.79 mmole per liter), triglycerides (75 mg per dl), 
and protein (3.8 gm per dl) were significantly higher in 
malignant ascites compared to the median AF concen- 
trations of cholesterol (20 mg per dl), phospholipids (0.33 
mmole per liter), triglycerides (51 mg per dl) and protein 
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FIG. 1. Scattergram distribution of AF phospholipids, triglycerides, 
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(1.9 gm per dl) in patients with cirrhosis (Figure 1). The 
best discriminating values were 48 mg per dl for choles- 
terol, 0.6 mmole per liter for phospholipids, 65 mg per dl 
for triglycerides and 2.5 gm per dl for protein. 
AF concentrations of lipids and protein in the 38 
subsequent patients are illustrated in Table 1. 
Applying the discrimination values defined from the 
data of the first 54 patients to the 38 subsequent patients, 
sensitivity, specificity and efficiency were calculated (Ta- 
ble 2). Diagnostic efficiency ranged between 68.4 and 
86.8% in this reevaluation study, and cholesterol and 
phospholipid determinations were superior to the other 
parameters. From the results of all 92 patients, an effi- 
ciency of 92.3% for cholesterol, 79.4% for phospholipids, 
72.8% for triglycerides and 79.4% for protein was calcu- 
lated (Table 3). AF cholesterol measurement yielded the 
best discrimination: only 5 patients with malignant and 
2 patients with cirrhotic ascites were incorrectly classi- 
fied at a cutoff concentration of 48 mg per dl. 
Cytological examination was performed in 28 of 41 
patients with nonmalignant ascites and in 37 of 51 pa- 
tients with ascites due to malignant neoplasms. Diagnos- 
tic specificity was found to be 100%. However, sensitivity 
was only 62% because of a great number of false-negative 
results. There was no correlation between the concentra- 
tions of triglycerides and the other lipids or total protein 
in AF of the 92 patients, indicating a different mecha- 
nism of triglyceride accumulation in ascites. However, 
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cholesterol and total protein in 23 patients with liver disease (L.D.) and 
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TABLE 1. CONCENTRATION OF AF LIPIDS AND PROTEIN IN PATIENTS WITH CIRRHOTIC AND MALIGNANT ASCITES 
No. of Cholesterol Phospholipids Triglycerides Protein 
patients (mg/dl) (mmolefliter) [ mgf dl ) (Em/&) 
Cirrhotic ascites 
Median 
Range 
Mean f S.D. 
Malignant ascites 
Median 
Range 
Mean f S.D. 
18 
23 0.32 32 1.9 
4-62 0.08-0.69 15-275 0.2-5.4 
26.5 f 17.3 0.37 f 0.18 51 f 59 2.1 f 1.5 
20 
70" 0.75" 68 4.0" 
74 f 26 0.76 f 0.18 76 f 50 4.0 -t 1.0 
34-140 0.56-1.32 33-187 2.1-5.4 
Difference between the mean of cirrhotic and malignant concentrations is statistically significant, p < 0.001 
Not statistically significant. 
TABLE 2. DIAGNOSTIC VALUE OF ASCITIC LIPIDS A N D  PROTEIN 
FROM ASCITES DUE TO VARIOUS NEOPLASMS ( n = 2 0 )  
FOR SEPARATING ASCITES OF NONMALIGNANT ORIGIN (n = 18) 
TABLE 3. DIAGNOSTIC VALUE OF ASCITIC LIPIDS AND PROTEIN 
FOR SEPARATING ASCITES OF NONMALIGNANT ORIGIN (n = 41) 
FROM ASCITES DUE TO VARIOUS NEOPLASMS (n = 51) 
Discrimination Sensitivity Specificity Efficiency 
value (9;)  ( v m )  (%) 
Discrimination Sensitivity Specificity Efficiency 
value (%) (%) (%) 
Cholesterol 48 mg/dl 85.0 88.9 86.8 
Phospholipids 0.6 mmole/liter 85.0 88.9 86.8 
Triglycerides 65 mg/dl 65.0 72.2 68.4 
Protein 2.5 gm/dl 85.0 12.2 79.0 
significantly positive correlations were found between 
cholesterol/phospholipids (r = 0.59), cholesterol/total 
protein (r = 0.56) and phospholipidsjtotal protein (r = 
0.55) (Figure 2, a to c). 
Table 4 presents concentrations of AF lipids and pro- 
tein found in seven patients with both chronic liver 
disease and malignancy. In three subjects, posthepatitic 
cirrhosis was the underlying disease associated with a 
histologically proven hepatocellular carcinoma. Low AF 
cholesterol levels of 5 to 11 mg per dl suggested that 
ascites was most likely caused by cirrhosis. In two pa- 
tients suffering from cirrhosis, a hepatocellular carci- 
noma was suggested by ultrasound and computed tomog- 
raphy but not proven by histological examination. One 
patient had Laennec's cirrhosis and a history of carci- 
nomas of the breast and thyroid, which had been oper- 
ated successfully years ago. There was no clinical evi- 
dence of metastases. AF cytology was negative, choles- 
terol, protein and triglycerides were below the cutoff 
values and only phospholipids were slightly elevated. 
Another cirrhotic suffered from an osteofibrosis, the 
cause of which could not clarified, but chronic myeloid 
leukemia could not be excluded with certainty. 
DISCUSSION 
In 1958, Rovelstad et al. (3) reported elevated total 
lipid concentrations in the ascites of patients with ma- 
lignant neoplasms. Polak et al. (11)  demonstrated a 
marked elevation of total cholesterol in malignant and 
inflammatory AF compared to cirrhotic ascitic fluid. In 
the present study, we investigated the value of AF lipids 
in the discrimination of ascites caused by chronic liver 
disease and ascites due to malignancies. 
In a preliminary study of 54 patients (Figure l), 29 of 
31 patients with malignant ascites had an AF cholesterol 
concentration higher than 48 mg per dl, while all 23 
Cholesterol 48 mg/dl 90.1 95.1 92.3 
Triglycerides 65 mg/dl 72.5 73.1 72.8 
Phospholipids 0.6 mmole/liter 72.5 85.3 79.4 
Protein 2.5 gm/dl 82.3 75.6 79.4 
patients with ascites and chronic liver disease showed 
AF cholesterol below this value. The efficiency of AF 
cholesterol in the discrimination of malignant from cir- 
rhotic ascites was slightly lower (86.8%) in a prospective 
reevaluation of 38 subsequent patients. An equal effi- 
ciency in these 38 patients was calculated for AF phos- 
pholipids, while triglyceride and protein determinations 
were less effective. In the total of 92 patients, AF choles- 
terol determination was superior to the other parameters 
with a diagnostic efficiency of 92.3% compared to 79.4% 
for phospholipids, 72.8% for triglycerides and 79.4% for 
total protein. 
There was a positive correlation between AF concen- 
trations of cholesterol, phospholipids and protein but not 
between these and AF triglycerides. The potential ra- 
tionale for these observations is most likely an increased 
filtration of plasma proteins and lipoproteins in the 
presence of peritoneal disorders such as peritoneal car- 
cinomatosis. In accordance with this suggestion, plasma 
lipoproteins have been isolated and characterized from 
human AF recently (16). Although it is known that 
patients with cirrhosis often present low plasma choles- 
terol levels, this observation could not explain solely the 
large difference between the AF cholesterol in cirrhotic 
and malignant ascites. In some of the patients, plasma 
cholesterol and AF cholesterol were determined simul- 
taneously. No significant difference was obtained be- 
tween plasma levels of cholesterol in patients with 
chronic liver disease and patients with malignancies. 
Plasma AF gradients of cholesterol were increased in 
liver disease compared to malignancies due to low AF 
cholesterol. However, plasma-AF gradients of cholesterol 
did not provide a better discrimination than the AF 
cholesterol concentration alone. 
Nevertheless, plasma AF gradients of proteins might 
be of greater diagnostic value than the determination of 
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FIG. 2. (a) Correlation of ascitic phospholipids and cholesterol in 92 patients with ascites of malignant or nonmalignant origin (r = 0.59; p < 
0.001). (b) Correlation of ascitic cholesterol and protein in 92 patients with ascites of malignant or nonmalignant origin (I = 0.56; p < 0.001). (c) 
Correlation of ascitic phospholipids and total protein in 92 patients with ascites of malignant or nonmalignant origin (r = 0.55; p < 0.001). 
TABLE 4. CONCENTRATION OF ASCITIC LIPIDS AND PROTEIN IN 
SEVEN PATIENTS WITH ASCITES WHOSE ORIGIN COULD NOT BE 
CLEARLY CLASSIFIED 
Cholesterol Triglycerides Phospholipids Protein 
(mg/dl) (mg/dl) (mmole/liter) (gm/dl) Diagnosis 
Cirrhosis and hepato- 11 184 0.21 0.8 
cellular carcinoma 
cellular carcinoma 
cellular carcinoma 
pected hepatocellu- 
lar carcinoma 
pected hepatocellu- 
lar carcinoma 
and thyroid carci- 
noma 
rhosis 
Cirrhosis and hepato- 5 12 0.09 1.5 
Cirrhosis and hepato- 11 33 0.22 4.2 
Cirrhosis and sus- 17 27 0.36 0.7 
Cirrhosis and sus- 29 45 0.52 3.2 
Cirrhosis, mammary 26 14 0.65 0.9 
Osteofibrosis and cir- 22 80 0.33 2.7 
protein in AF only. In a recent study, Pare et al. (17) 
reported protein concentrations in cirrhotic or malignant 
ascites similar to those measured in our study. 
Diagnostic efficiency of AF total protein determination 
was 80% in Pare’s study as well as in our investigation. 
Measurements of the AF to plasma ratio of total protein 
showed a similar efficiency in the discrimination of cir- 
rhotic and malignant ascites as the determination of 
total AF protein alone. 
However, diagnostic accuracy was much higher (95%) 
for the plasma AF albumin gradient. In a recent study, 
Scholmerich et al. (18) demonstrated an excellent differ- 
entiation between malignant and nonmalignant ascites 
by the AF fibronectin concentration. 
There is no doubt that the differential diagnosis of 
ascites can be improved by measurements of serum AF 
albumin gradient or fibronectin concentration. Our data 
suggest that the determination of AF cholesterol offers 
an equally effective discriminating test. However, the 
measurement of cholesterol might have considerable ad- 
vantages in terms of simplicity and cost effectiveness. 
As stated before, there was a positive correlation be- 
tween AF concentrations of cholesterol and phospholip- 
ids, indicating a possible common mechanism of accu- 
mulation. Surprisingly, phospholipid determinations 
have been found less helpful for the discrimination of 
cirrhotic from malignant AF. This might be partially 
related to the method of extracting lipid from AF samples 
with organic solvents. Preliminary results suggest that a 
newly developed enzymatic method for phospholipid 
quantitation is more effective for this purpose (19). 
No significant correlation was observed between AF 
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cholesterol and triglyceride concentrations in AF. The 
concentration of triglycerides in AF is of no practical 
value in the differential diagnosis of ascites. The reason 
for these findings is not clearly understood. One possible 
explanation might be that triglycerides in AF are derived 
HK. Carcinoembryonales Antigen (CEA) und CEA-like Aktivitiit 
in Ascites und Pleuraergiissen. Klin Wochenschr 1979; 57575-579. 
7. Nystrom JS, Dyce B, Wads d, et al. Carcinoembryonic antigen 
titers in effusion fluid. Arch Intern Med 1977; 137875-879. 
8. Svanberg L, Astedt B. Coaguiative and fibrinolytic properties of 
ascitic fluid associated with ovarian tumors. Cancer 1975 35:1382- 
only in part from plasma, but chylomicrons of intestinal 
origin in variable amounts may contribute to the total 
amount of triglycerides in AF. 
Further investigations are needed to elucidate the 
pathophysiology of lipid accumulations in the AF of 
patients with chronic liver disease, inflammatory and 
malignant peritoneal disorders. 
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